

## anti-inflammototy and immuno-therapy - all results

Treatment	Number of studies	clinical deterioration	clinical improvement	deaths	viral clearance
Immunostimulants drugs	80 studies <sup>1</sup>	0.86 [0.74 ; 1.01], 12 RCTs, I2=0% demonstrated inconclusive result	1.11 [1.00 ; 1.24], 20 RCTs, I2=35% demonstrated inconclusive result	0.89 [0.80 ; 0.98], 70 RCTs, I2=27% demonstrated moderate degree of certainty	3.02 [1.30 ; 7.02], 9 RCTs, I2=83% moderate degree of certainty
Immunosuppressants drugs	69 studies <sup>2</sup>	0.70 [0.51 ; 0.96], 11 RCTs, I2=59% demonstrated moderate degree of certainty	1.25 [1.13 ; 1.38], 14 RCTs, I2=15% demonstrated high degree of certainty	0.77 [0.69 ; 0.86], 44 RCTs, I2=22% demonstrated safety concern inconclusive result	-
anti-inflammatory therapies	26 studies <sup>3</sup>	0.18 [0.05 ; 0.57], 4 RCTs, I2=14% moderate degree of certainty	10.27 [1.17 ; 90.18], 1 RCT, I2=0% certainty unassessable	0.99 [0.94 ; 1.05], 12 RCTs, I2=0% inconclusive result	1.71 [0.80 ; 3.64], 1 RCT, I2=0% inconclusive result
corticosteroids	22 studies <sup>4</sup>	0.67 [0.44 ; 1.03], 2 RCTs, I2=0% inconclusive result	1.44 [0.89 ; 2.33], 4 RCTs, I2=65% inconclusive result	0.85 [0.73 ; 0.99], 15 RCTs, I2=64% demonstrated moderate degree of certainty	1.78 [1.06 ; 3.00], 1 RCT, I2=0% certainty unassessable
Kinase inhibitors	3 studies <sup>5</sup>	-	-	-	-
leflunomide	1 study <sup>6</sup>	1.00 [0.02 ; 52.54], 1 RCT, I2=0% inconclusive result	-	1.00 [0.02 ; 52.54], 1 RCT, I2=0% inconclusive result	-

### Notes

<sup>1</sup> ACTIV-3/TICO (tixa), 2022 (NCT04501978); Baldeon, 2022 (SRCTN85216856); ITAC, 2022 (NCT04546581); SPRINTER, 2022 (NCT04732949); ACTIV-3 (BRII-196 and BRII-198), 2021 (NCT04501978); ACTIV-3/ TICO (sotrovimab), 2021 (NCT04501978); ASCOT, 2021 (NCT04483960); Bennett-Guerrero, 2021 (NCT04344535); CAPSID, 2021 (NCT04433910); CCAP-2, 2021 (NCT04345289); Co-CLARITY, 2021 (NCT04567173); CONCOR-1, 2021 (NCT04348656); CONTAIN COVID-19, 2021 (NCT04364737); COP-COVID-19, 2021 (NCT04358783); CP-COVID-19, 2021 (NCT04332835); CPC-SARS, 2021 (NCT04405310); Darazam, 2021 (NCT04521400); Darazam (COVIFERON Interferon beta-1a), 2021 (NCT04343768); Darazam (COVIFERON Interferon beta-1b), 2021 (NCT04343768); DAWN-Plasma, 2021 (NCT04429854); Holm K, 2021 (NCT04600440); Kalil (ACTT-3), 2021 (NCT04492475); Kirenga, 2021 (NCT04542941); LACCPT, 2021 (PACTR202006760881890); Li, 2021 (ChiCTR2000029638); LIFESAVER, 2021 (NCT04374526); Lopardo, 2021 (NCT04494984); Menichetti, 2021 (NCT04716556); NCT04385199, 2021 (NCT04385199); NCT04397757, 2021 (NCT04397757); NCT04403477 (two doses), 2021 (NCT04403477); NCT04442191, 2021 (NCT04442191); NCT04528368, 2021 (NCT04528368); O'Donnell, 2021 (NCT04359810); Pandit, 2021 (CTRI/2020/06/026087); PC/COVID-19, 2021 (NCT04366245); PERUCONPLASMA, 2021 (NCT04497324); PLACO-COVID, 2021 (NCT04428021); Pouladzadeh, 2021 (IRCT20200310046736N1); Raman, 2021 (CTRI/2020/06/026222); RECOVER, 2021 (EudCT 2020-001632-10); RECOVERY (plasma), 2021 (NCT04381936); RECOVERY (REGN-COV2), 2021 (NCT04381936); REMAP-CAP (plasma), 2021 (NCT02735707); Sekine (PLACOVID), 2021 (NCT04547660); Shashi Bhushan, 2021 (CTRI/2020/12/029855); Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 (NCT04426695); ACTIV-3/TICO LY-CoV555, 2020 (NCT04501978); Al-Qahtani, 2020 (NCT04356534); Balcells, 2020 (NCT04375098); ConCOVID (Gharbharan et al.), 2020 (NCT04342182); CONFIDENT, 2020 (NCT04558476); ConPlas-19, 2020 (NCT04345523); COPLA-II trial, 2020 (NCT04425915); Davoudi-Monfared, 2020 (IRCT20100228003449N2); Esquivel-Moynelo, 2020 (RPCEC0000307); Fu, 2020 (ChiCTR2000030262); Gharebaghi, 2020 (IRCT20200501047259N1);

ILBS-COVID-02 (Bajpai M), 2020 (NCT04346446); Jagannathan, 2020 (NCT04331899); Li, 2020 (ChiCTR2000029757); Libster, 2020 (NCT04479163); PICP19 (Ray), 2020 (CTRI/2020/05/025209); PLACID, 2020 (CTRI/2020/04/024775); PlasmAr, 2020 (NCT04344535); Rahmani, 2020 (IRCT20100228003449N2); Rasheed, 2020 (); Sakoulas, 2020 (NCT04411667); Salman, 2020 (NCT04530370); SOLIDARITY (interferon), 2020 (NCT04315948); Synairgen SG016, 2020 (NCT04385095); Tabarsi, 2020 (IRCT20151227025726N2); Abolghasemi, 2020 (IRCT20200325046860N1); Duan, 2020 (); Hegerova, 2020 (); Salazar, 2020 (); Sean, 2020 (); Bihariesingh-Sanchit (SuriCovid), 2021 (ISRCTN18304314); Cai -FAVIPRAVIR, 2020 (ChiCTR2000029600); Joyner, 2020 (NCT04338360)

<sup>2</sup>COV-BARRIER (critically ill), 2022 (NCT04421027); Murugesan, 2022 (); RECOVERY, 2022 (NCT04381936); Amra, 2021 (IRCT20170207032444N3); CORIMUNO-ANA-1, 2021 (NCT04341584); CORIMUNO-SARI-1 (non ICU), 2021 (NCT04324073); COV-BARRIER, 2021 (NCT04421027); Declercq J (COV-AID), 2021 (NCT04330638); Fakharian, 2021 (IRCT20151227025726N2); Hamed, 2021 (); Kumar, 2021 (CTRI/2020/05/024959); Lescure (Sarilumab 200mg), 2021 (NCT04327388); Lescure (Sarilumab 400mg), 2021 (NCT04327388); LIVE-AIR (Temesgen), 2021 (NCT04351152); MARIPOSA, 2021 (NCT04363736); Rashad, 2021 (NCT04519385); RCT-TCZ-COVID-19, 2021 (NCT04346355); RECOVERY, 2021 (NCT04381936); REMAP-CAP (tocilizumab), 2021 (NCT02735707); REMAP-CAP sarilumab, 2021 (NCT02735707); Rosas (REMDACTA), 2021 (NCT04409262); Rutgers, 2021 (); SAVE-MORE, 2021 (NCT04680949); Singh (TD-0903 10mg), 2021 (NCT04402866); Singh (TD-0903 1mg), 2021 (NCT04402866); Singh (TD-0903 3mg), 2021 (NCT04402866); Soin AS (COVINTOC), 2021 (CTRI/2020/05/025369); STOP-COVID (Guimarães), 2021 (NCT04469114); Talaschian, 2021 (IRCT20081027001411N4); Veiga, 2021 (NCT04403685); ACTIV-1 abatacept, 2020 (NCT04593940); ACTIV-1 cenicriviroc, 2020 (NCT04593940); ACTT-2 (Kalil), 2020 (NCT04401579); BACC Bay Tocilizumab Trial, 2020 (NCT04356937); CAN-COVID, 2020 (NCT04362813); Cao, 2020 (); CORIMUNO-TOCI-1 (Group 1), 2020 (NCT04331808); CORIMUNO-TOCI-ICU (Group 2), 2020 (NCT04331808); COVACTA (Rosas), 2020 (NCT04320615); Dongsheng Wang, 2020 (ChiCTR2000029765); EMPACTA, 2020 (NCT04372186); ACTIV-1 infliximab, 0 (NCT04593940); DEVENT, 0 (NCT04377620); EU-CTR2020-001375-32 (PreToVid), 0 (EU-CTR2020-001375-32); EU-CTR2020-001748-24 (ImmCoVA), 0 (EU-CTR2020-001748-24); NCT04377750 (HMO-0224-20), 0 (NCT04377750); NCT04412772 (ARCHITECTS), 0 (NCT04412772); NCT04434717 (COVITOX-1 single dose plus two doses), 0 (NCT04434717); NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0 (NCT04479358); NCT04577534 (COVIDSTORM), 0 (NCT04577534); sarilumab Sanofi phase 3 outside US, 0 (); sarilumab Sanofi phase 3 US, 0 (NCT04315298); TOCOVID, 0 (NCT04332094); Rodriguez-Garcia, 2020 (EUPAS34966); Tziolos, 2021 (); Andrew, 2020 (); ARI-RAF (Della-Torre), 2020 (); Biran, 2020 (); Cantini, 2020 (); Capra, 2020 (); Colaneri, 2020 (); HNF Hospital Tocilizumab multidisciplinary team, 2020 (); Martinez-Sanz, 2020 (); Mathilde, 2020 (); Rojas-Marte, 2020 (); Rossotti, 2020 (); Somers, 2020 (); TOCI-RAF Study Group (Campochiaro), 2020 (); Tsai, 2020 ()

<sup>3</sup>COL-COVID (Pascual-Figal), 2021 (NCT04350320); COLCHIVID, 2021 (NCT04367168); COLCOVID, 2021 (NCT04328480); Gaitan-Duarte (Rosuvastatin plus colchicine), 2021 (NCT04359095); Horby, 2021 (NCT04381936); Lanzoni, 2021 (NCT04355728); MASH-COVID (Cremer), 2021 (NCT04399980); Rashad (CLARI vs SoC), 2021 (); Ravichandran, 2021 (CTRI/2021/05/033544); RECOVERY (colchicine), 2021 (NCT04381936); GRECCO-19, 2020 (NCT04326790); Lopes MIF, 2020 (RBR-8jyhxx); Salehzadeh, 2020 (IRCT20200418047126N1); Shi, 2020 (NCT04288102); Shu, 2020 (ChiCTR2000031494); Drake, 2021 (); Bruce, 2020 (); Ravichandran, 2020 (); Sandhu, 2020 (); Wenxin, 2020 (ChiCTR2000031630.); Brunetti, 2020 (); Imam, 2020 (); Malgorzata, 2020 (); Scarsi, 2020 (); Jeong, 2020 (); Tsiakos, 2020 (NCT04398004)

<sup>4</sup>COVID STEROID 2, 2021 (NCT04509973); Jamaati, 2021 (IRCT20151227025726N1); Munch (COVID-STERIOD), 2021 (NCT04348305); Ranjbar, 2021 (IRCT20200204046369N1); Rashad, 2021 (NCT04519385); CAPE-COVID, 2020 (NCT02517489); CODEX (Tomazini), 2020 (NCT04327401); DEXA-COVID19, 2020 (NCT04325061); Edalatifard, 2020 (IRCT20200404046947N1); Farahani, 2020 (IRCT20200406046963N1); GLUCOCOVID, 2020 (2020-001934-37); Metcovid, 2020 (NCT04343729); RECOVERY dexamethasone, 2020 (NCT04381936); REMAP-CAP, fixed 7-day course, 2020 (NCT02735707); REMAP-CAP, shock-dependent course, 2020 (NCT02735707); Steroids-SARI, 2020 (NCT04244591); Tang X, 2020 (NCT04273321); Fernández Cruz, 2020 (); Jianfeng, 2020 (); Raef, 2020 (); Tomasz, 2020 (); Lu, 2020 ()

<sup>5</sup>Covid-19 HUF, 2021 (NCT04346147); CALAVI, 2020 (NCT04346199); CALAVI US, 2020 (NCT04380688)

<sup>6</sup>Wang, 2020 (ChiCTR2000030058)